Alle får, ingen fare for det
Du tror altså ikke at Ling har snakket med Nieba om grunnene til den gode guidingen og storyen bak de 14 nye pasientene i Q4?
Han sitter egentlig bare å gjetter når han forteller om hvorfor han ble så positivt overrasket over rekrutteringsfarten?
Mener du Ling sitter på info fra Nieba som angår rekrutteringen som selskapet ikke uoppfordret deler med de øvrige aksjonærene?
3 Likes
Om de ikke har delt den informasjonen vet jeg ikke. Har ikke lest transcript fra Q4, ei heller deltatt på Carnegie-seminaret.
Men ja, jeg tror Ling har fått verifisert denne informasjonen siden han deler den på en podkast som «halve» biotek-Norge hører på.
2 Likes
Jeg hørte podcasten men fikk ikke med meg at det ble delt nyheter om hva som har skjedd i kulissene (storyen bak) med de 14 pasientene som det er snakk om annet enn at han tror det er ett resultat av de tiltakene de har uttalt seg om.
3 Likes
Jeg har lært meg at man kommer lengst her i verden med å være ydmyk. Jeg lyttet en gang til nå, og når han snakker om rekrutteringen og utviklingen på denne, så sier han:
«Utveklingen har, skal jeg gissa…»
Så helt korrekt, han antar fordi it makes sense at det øker måned for måned siden de guider på å øke videre i farten ut fra snittet i Q4.
My wrong, Ling spekulerer altså så det synger etter 
Men det er veldig god spekulasjon da. Jeg spekulerer i at han har rett i sine antakelser.
13 Likes
Kursen synker i Nano. Det er neppe uventet. Jeg tror det rett og slett er Covid-19 som gir frykt for at tidsskjemaet ikke vil holde. Mars og april blir tunge covidmåneder, men regner med at det løsner kraftig i mai og utover. Astra Zeneca-vaksinen er ikke avgjørende. Det vil være plenty med annen vaksine fom mai.
Dette kan dermed være en god anledning til å laste opp, selv om vi ikke vil få nyheter før “in some few months”, senest 30. juni når kohort 2 i Archer-1 kommer. Ut fra det Nieba uttaler om kohort 2 har ikke Nanov-aksjonærene mye å frykte, men bør benytte lave kurser til akkumulering.
1 Like
Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer
35 Likes
Flere enn meg som fant en tannlege? Gjør et nytt søk…
Er vel like vanlig som Ola H Nordmann hehe. Ikke det enkleste navnet å google.
Spennende!
Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer
WED, MAR 17, 2021 23:55 CET
Oslo, Norway, 17 March 2021
Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun as Chief Executive Officer (CEO). He will take up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland.
Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”).
During his career at Roche, Mr Braun led the Lifecycle Management teams for the successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva® (erlotinib).
Mr Braun has also held various operational leadership positions including being country general manager and multiple commercial roles in Europe, US and Latin America. He has developed expertise across multiple strategic and operational roles including development, manufacturing, business development and market access for innovative therapeutic products in several geographies and other therapeutic areas, including rare diseases and infectious diseases.
In addition to his experience at Roche, Mr Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies.
Jan H. Egberts, Chairman of Nordic Nanovector’s Board of Directors, said: “I am delighted that Peter has agreed to join us at this important time for Nordic Nanovector. Our aim was to leverage on our important recent progress by recruiting a strong commercial CEO who can refine and drive the company’s plans towards the regulatory filing and commercialisation of Betalutin®. We are confident that, with Peter’s track record in and enthusiasm for the development and commercialisation of innovative targeted oncology products, we can build on the top-line data from the PARADIGME trial expected later in the year by clearly defining our plans for Betalutin®’s commercialisation. These are key steps on our path to becoming a leader in targeted radiopharmaceuticals.”
“I would like to take this opportunity to thank Lars Nieba for his leadership of the company during the last 12 months as Interim CEO. His dedication and efforts have contributed to the considerable progress Nordic Nanovector has made in this time.”
Mr Braun added: “I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that targeted cancer therapeutics represent an important treatment modality and well tolerated, targeted radiopharmaceuticals, such as Betalutin®, can make a real difference to patients. I look forward to working closely with the Board and the leadership team to bring this innovative drug to NHL patients worldwide.”
When joining Nordic Nanovector, Mr Braun will be granted 350,000 PSUs (performance share units) as part of the company’s annual grant of PSUs in the first quarter of 2021.
For further information about the PSUs and the related warrants, see page 28 in the company’s annual report for 2019.
3 Likes
Til Nieba. Får håpe han blir værende.
5 Likes
Fant et klipp hvertfall
6 Likes
7 Likes
Lars forblir CTO vil jeg tro 
1 Like
Endelig en CEO som snakker dønn perfekt engelsk.
2 Likes
Roche has entered the lobby…?
6 Likes
Tenkte det samme
Tiden for «lost in translation» og spekulative tolkninger er kanskje herved over